Amarin Corp Plc (AMRN)

[Whalatane]

OneRag. just coming back to this briefly
I think Atom was referring to the diabetic plus 1 risk factor as his designated primary prevention group .
This is far less then the entire primary prevention group which is basically everyone on a statin who has not had an “ event “

JL is making the case ( I think ) that Vascepa should be added to all at risk of a CV event .

I agree with that ... benefit far outweighs risk ... but doubt the FDA will go that far . I do expect a label covering the inclusion requirements for R-It .... but expect as JL pointed out ... that MD ‘s will prescribe for a far wider patient population because V is so safe .

I’m not understanding where Atom is going with his Ezetimibe and R-It outcome line of thought , Ezetimibe is mainly used to lower LDL cholesterol , especially for those that have difficulty with Statins .

Do you recall any Outcome trials with Ezetimibe ?
R-It’s Outcome trial is the gold standard IMHO

Kiwi